(Q61979154)

English

Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

clinical trial

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

short name

HEMOS AML 0106 (English)

0 references

title

Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years) (English)

0 references

medical condition

leukemia

0 references

sponsor

University of Bologna

0 references

country

Italy

0 references

start time

March 2007